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ABSTRACT
 
The methods employed in the development of needs-
based quality of life (QoL) instruments have evolved
with time as advances have been made in the ﬁeld
of psychometrics and as experience has grown. This
paper illustrates the current instrument development
methodology with reference to three needs-based
QoL measures recently developed for use in
dermatology:
• The Quality of Life Index for Atopic Dermatitis
(QoLIAD);
• The Psoriasis Index of Quality of Life (PSORIQoL);
and
• The Parents’ Index of Quality of Life—Atopic Derma-
titis (PIQoL-AD).
Keywords: PIQoL-AD, PSORIQoL, psychometric proper-
ties, QoLIAD, quality of life.
 
Item Generation and Selection
 
A summary of the stages used in the development of
the three needs-based instruments is shown in
Table 1.
 
Qualitative Patient Interviews
 
In order to minimize ethnocentricity associated with
deriving questionnaire content in a single country,
interviews were conducted in the UK (the lead coun-
try) and an additional northern and southern Euro-
pean country. For both the Quality of Life Index for
Atopic Dermatitis (QoLIAD) and the Parents’ Index
of Quality of Life—Atopic Dermatitis (PIQoL-AD),
65 qualitative interviews were conducted with rele-
vant adults in the UK, the Netherlands, and Italy.
The interviews were unstructured and designed to
explore the QoL impact of atopic dermatitis (AD)
on the individual (for the QoLIAD) or on the whole
family (PIQoL-AD). The purpose of the latter ques-
tionnaire was later reﬁned to assess the QoL of the
principal carer of the child with AD. In the case of
the PSORIQoL, 62 interviews were conducted with
adult patients with psoriasis in the same three
countries.
The qualitative interviews are designed to allow
interviewees to raise those issues that they consid-
ered important to their QoL. Rather than starting
with a list of potential areas that should be assessed,
the interviewer prompts and guides the interviewee
to go beyond a simple listing of symptoms and loss
of functionality. In this way it is possible to look at
how these direct impacts of the disease actually
affect the needs of patients. For example, rather
than simply accepting that a skin disease is
unsightly, the interviewer would investigate further
to determine whether this affects needs related to
fashion, self-image, socialization, or other areas of
experience. The aim is always to allow the inter-
viewee to dictate the direction of the interview and
to express the issues in their own words.
Interviews are generally performed in the
patient’s own home—a more relaxing environment
than a clinic or the researcher’s ofﬁces—and last
between one and four hours. Almost all interview-
ees ﬁnd the experience pleasurable as they are given
the opportunity to express their distress to an inter-
ested listener—an opportunity that may not be
offered by family and friends.
 
Production and Analysis of  Interview Transcripts
 
All interviews are audio-recorded and transcripts
are produced. Each transcript is analyzed independ-
ently by at least two experienced researchers. Their
task is to identify statements relating to needs that
are affected by the disease in question. These state-
ments are then grouped according to topic. For
example, in the case of the PSORIQoL; issues
related to control over the disease, identity, time
structure, self-esteem, self-consciousness, independ-
ence, impact on relationships and social life, reac-
tion of others, and fears about the future.
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The analyses produce a list of several hundred
potential items for each measure. Results from the
three countries were integrated at an international
meeting between the researchers involved in the
study and others from France, Germany, Spain, and
the United States. This allowed the potential items
to be tested for cultural applicability to a wider
range of countries. Items that were considered to be
inapplicable or inappropriate to any of these coun-
tries (for example, where the concept conveyed was
not considered relevant) were removed from the
item pool.
The wording of items selected for the instrument
is taken, as far as possible, directly from the inter-
view transcripts. Each item is selected on the basis
of the following criteria:
• reﬂects needs that are affected by the disease;
• covers issues that have been raised in all three
countries;
• applicable to all potential respondents;
• expressed in the ﬁrst person;
• reﬂects a single idea;
• unambiguous;
• short and simple; and
• does not duplicate other items.
This process reduces the size of the potential pool
of items considerably.
 
Cocalibration
 
Some identical items arose in the interviews with
both AD and psoriasis patients were selected for
both the QoLIAD and PSORIQoL. This was to ena-
ble future valid comparisons to be made between
the impacts of these diseases on QoL.
 
Production of  Draft Questionnaires
 
Initial versions of the QoLIAD and PIQoL-AD were
produced for the UK, US, the Netherlands, Italy,
Germany, and France. Spanish versions were pro-
duced following the ﬁnalization of the instrument
and thus, although reported alongside those of the
other countries, the Spanish versions did not form
part of the parallel development process.
International development of the PSORIQoL
was delayed in order to give priority to the measures
for atopic dermatitis. However, development of the
measure for the UK continued [1]. Subsequently, an
adaptation of the PSORIQoL for the US has been
completed [2] and new versions are in development
for Europe.
Language adaptations were produced using the
dual panel methodology recommended by Hunt
and colleagues [3]. For the US, the Netherlands, and
Italy a single translation panel was conducted. This
panel comprised lay individuals of average educa-
tional level who were considered to be typical of the
target population. For France, Germany, and Spain
a bilingual panel consisting of speakers of the target
language who were also ﬂuent in English was con-
ducted prior to the lay panel.
 
Testing the Psychometric Properties of the 
New Measures
 
Field Testing
 
Initial  testing  of  the  new  instruments  was  aimed
at  establishing  their  face  and  content  validity.
The appropriateness and acceptability of the new
measures was evaluated formally by means of
semistructured interviews conducted with app-
roximately 20 patients in each country. Inter-
viewees were asked to complete the questionnaire
in the presence of an interviewer and then to
comment on its applicability, comprehensibility,
relevance, and comprehensiveness. Items that were
found to be problematic in one or more countries
were considered for removal. New draft versions
of each of the measures were prepared following
this exercise.
 
Validation Surveys
 
A separate postal survey for each of the three instru-
ments was conducted in each country to reduce the
number of items and to establish their psychometric
properties. A total of 1085 patients were involved in
the validation of the QoLIAD and 979 parents con-
tributed to the validation of the PIQoL-AD. The UK
PSORIQoL validation study involved 148 psoriasis
patients.
Respondents in each country were asked to com-
plete the questionnaire under test, the Dermatology
Life Quality Index (DLQI; despite its name, a meas-
ure of symptoms and functioning [4]) and the Psy-
chological General Well-Being Schedule (PGWB [5];
or the equivalent instrument in the UK, the General
Well-Being Index, GWBI [6]) on two occasions, two
weeks apart.
 
Table 1
 
Stages in instrument development
 
Item generation and selection
 
Qualitative patient interviews in three countries
Production of  interview transcripts
Content analysis of  transcripts
Production of  draft questionnaires (all language versions)
 
Testing psychometric and scaling properties
 
Field-test interviews (face and content validity)
Postal validation survey (scalability, internal consistency, 
reproducibility, and construct validity)
Data analyses and identiﬁcation of  ﬁnal instrument
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Reproducibility of the ﬁnal version of each meas-
ure was assessed using the test–retest method. A
reliability correlation of 0.85 or higher was required
for an instrument to be used in clinical trials [7].
Internal consistency coefﬁcients below 0.70 were
considered indicative of individual items not con-
tributing adequately to the overall scale [8].
Convergent and divergent validity of the meas-
ures were assessed through association with the
DLQI and PGWB. Moderate to moderately high
correlations (0.5–0.7) were expected between the
QoL measures and the PGWB/GWBI, whereas
higher correlations (0.6–0.8) were expected with
the DLQI (a dermatology-speciﬁc instrument).
Known groups validity was assessed by relating
scores on the measures to; reported severity of dis-
ease, current ﬂare of symptoms, and general health.
It was anticipated that patients/parents who re-
ported poorer perceptions of these variables would
obtain worse scores on the QoL measures.
 
Development of the PSORIQoL for the USA
 
Following the completion of the UK PSORIQoL an
adaptation was developed for the USA [2]. A lay
panel was employed to determine the most appro-
priate wording for the items and instructions. Field-
test interviews were conducted with 37 psoriasis
patients and 72 patients participated in the postal
validation survey. Similar variables were used to
establish known groups validity as had been
employed in the UK study.
 
Results of the Instrument Developments
 
Identiﬁcation of  Final Item Sets
 
PIQoL-AD.
 
Item response theory (Rasch model)
was applied to data from the validation studies con-
ducted in the UK, Netherlands, Germany, France,
and USA to reduce the number of items [9]. The aim
was to identify a ﬁnal item set that produced the
highest possible measurement quality across the dif-
ferent language versions. A number of factors were
taken into account in this process, including item
misﬁt, inter-item dependency, and item redundancy.
Item instability over time and differential item func-
tioning (variations in item calibrations by age or
gender) were found to be minimal.
There was considerable item misﬁt and substan-
tial levels of item interdependency in most language
versions of the 45-item measure [10]. It was hypoth-
esized that items requiring parents to provide a
proxy-response on their child’s behalf (e.g., “He is
very moody”) would not work in the same way as
items asking parents to respond for themselves (e.g.,
“I feel I have no time to relax”). Exploratory prin-
cipal components analysis conﬁrmed this hypothe-
sis and the 12 proxy-items were removed. A further
three items were deleted due to misﬁt and two more
as a result of high inter-item dependency. This
resulted in the ﬁnal 28-item version of the PIQoL-
AD.
 
QoLIAD.
 
Again the analyses were performed on
data derived from all the validation studies [11].
The variation of item parameters, derived from ﬁt-
ting the data to the Rasch model, across adminis-
trations, age, or gender did not justify the removal
of any items. Fifteen items were removed due to
item misﬁt and two as a result of item-interdepend-
ence. This resulted in the ﬁnal 25-item version of the
QoLIAD.
 
PSORIQoL.
 
Data from the PSORIQoL validation
study conducted in the UK were subjected to Rasch
analysis [1]. A 25-item version of the instrument
was identiﬁed that showed optimum ﬁt to the Rasch
model. Although three of these 25 items exhibited
marginal misﬁt all were found to be stable across
administrations.
 
Traditional Psychometric Properties of  the Three 
Instruments
 
Internal consistency and test–retest reliability.
 
Table 2 shows that all language versions of the three
measures have good internal consistency and test–
retest reliability. The only exception is the Dutch
QoLIAD. However, this is based on a sample of
only 18 patients; the ﬁgure for the Dutch DLQI is
also very low. In contrast to the QoLIAD, the
PIQoL-AD, and the PSORIQoL, it can be seen that
the reliability of the DLQI rarely meets an adequate
level. Such problems are also common for the
PGWB. The results suggest that the latter two meas-
ures would be expected to lack the responsiveness
necessary to detect change in health status in a clin-
ical trial setting.
 
Construct validity.
 
The results of the validation
studies were encouraging. All language versions of
the three measures were shown to be unidimen-
sional, consistent, reliable, and valid—the basic
requirements for construct validity.
In almost all cases the instruments were able to
distinguish respondents in terms of both perceived
general health and severity of skin condition. Fewer
of the validation studies were able to show differ-
ences associated with whether or not the condition
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was ﬂaring or whether lesions were visible on the
hands and/or face. Although trends were apparent
in almost all cases, unequal group sizes and the
effects of treatment may have obscured the actual
differences.
Results of the validation studies are summarized
in Table 3.
 
Conclusions
 
The development process described above is
designed to produce instruments with excellent psy-
chometric properties that are acceptable to respond-
ents and easy to administer. Given the results from
the validation studies, it is safe to conclude that the
instruments would be capable of detecting real
change in QoL associated with effective treatment.
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